HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Dutch translation Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Savulescu, J Articles by Clayton, M Search for Related Content PubMed PubMed Citation Articles by Savulescu, J Articles by Clayton, M

Why we should allow performance enhancing drugs in sport

¹ Uehiro Chair of Practical Ethics, University of Oxford, Oxford, UK
² Murdoch Childrens Research Institute, Melbourne, Victoria, Australia

Correspondence to:
Correspondence to:
Professor Savulescu
Flat 2, 3 Bradmore Road, Oxford OX2 6QW, UK; julian.savulescu@philosophy.ox.ac.uk

Abbreviations: EPO, erythropoietin; PCV, packed cell volume

Keywords: performance enhancing drugs

The first 150 words of the full text of this article appear below.

In 490 BC, the Persian Army landed on the plain of Marathon, 25 miles from Athens. The Athenians sent a messenger named Feidipides to Sparta to ask for help. He ran the 150 miles in two days. The Spartans were late. The Athenians attacked and, although outnumbered five to one, were victorious. Feidipides was sent to run back to Athens to report victory. On arrival, he screamed "We won" and dropped dead from exhaustion.

The marathon was run in the first modern Olympics in 1896, and in many ways the athletic ideal of modern athletes is inspired by the myth of the marathon. Their ideal is superhuman performance, at any cost.

DRUGS IN SPORT
The use of performance enhancing drugs in the modern Olympics is on record as early as the games of the third Olympiad, when Thomas Hicks won the marathon after receiving an injection of strychnine in the . . . [Full text of this article]

This article has been cited by other articles:

				C W Fuller and C J Ward An empirical approach for defining acceptable levels of risk: a case study in team sports Inj. Prev., August 1, 2008; 14(4): 256 - 261. [Abstract] [Full Text] [PDF]

				B. Kayser and A. C T Smith Globalisation of anti-doping: the reverse side of the medal BMJ, July 4, 2008; 337(jul04_1): a584 - a584. [Full Text]

				J Savulescu and B Foddy Sports ethics: an anthology Br. J. Sports Med., September 1, 2005; 39(9): 686 - 687. [Full Text] [PDF]